胃泌素释放肽前体和糖类抗原72-4在胃癌患者中的表达及临床意义  

Expression and clinical significance of pro-gastrin-releasing peptide and carbohydrate antigen 72-4 in patients with gastric cancer

作　　者：李礼[1] 孟海[2] 赵广春 于正清[1] 尹晓东[3] Li Li;Meng Hai;Zhao Guangchun;Yu Zhengqing;Yin Xiaodong(Department of Clinical Laboratory,Binhai People′s Hospital of Jiangsu Province,Binhai 224500,Chin)

机构地区：[1]江苏省滨海县人民医院检验科,224500 [2]江苏省滨海县人民医院消化内科,224500 [3]江苏省滨海县人民医院肿瘤科,224500

出　　处：《国际肿瘤学杂志》2018年第5期273-276,共4页Journal of International Oncology

摘　　要：目的探讨胃泌素释放肽前体（ProGRP）和糖类抗原724（CA724）在胃癌患者中的表达及临床应用价值。方法收集2014年1月至2016年12月，本院收治的90例胃癌患者和50例健康体检者，采用电化学发光法检测研究对象血清ProGRP和CA724水平，并分析ProGRP与胃癌临床病理特征、术后复发及CA724的关系。通过受试者工作特征（ROC）曲线分析ProGRP和CA724检测对胃癌的诊断价值。结果胃癌组患者血清ProGRP、CA724水平分别为（249.3±28.9）pg/ml、（148.8±33.5）U/ml，显著高于正常对照组的（14.4±7.6）pg/ml、（3.8±1.4）U/ml，差异均有统计学意义（t=56.320，P＜0.001；t=30.504，P＜0.001）。Ⅲ～Ⅳ期患者血清ProGRP水平［（269.1±30.9）pg/ml］显著高于Ⅰ～Ⅱ期患者［（198.5±23.9）pg/ml］，差异有统计学意义（t=11.200，P＜0.001），有淋巴结转移的患者血清ProGRP水平［（259.9±31.4）pg/ml］显著高于无淋巴结转移的患者［（190.3±26.8）pg/ml］，差异有统计学意义（t=9.500，P＜0.001）。术后1年复发患者血清ProGRP水平［（181.3±21.7）pg/ml］明显高于未复发患者［（26.1±12.8）pg/ml］，差异有统计学意义（t=31.830，P＜0.001）。胃癌患者血清ProGRP和CA724水平呈正相关（r=0.792，P=0.012）。ROC曲线显示，ProGRP取阈值为23.6 pg/ml时，其诊断胃癌的敏感性为80.0%，特异性为70.0%。CA724取阈值为11.2 U/ml时，其诊断胃癌的敏感性为60.0%，特异性为89.0%。ProGRP和CA724联合检测的敏感性和特异性分别为89.7%和94.8%，诊断价值优于单项检测（χ2=6.028，P=0.009；χ2=4.675，P=0.031）。结论胃癌患者血清中ProGRP和CA724水平显著升高且二者呈正相关，联合检测能够提高诊断敏感性和特异性。ProGRP与肿瘤分期、淋巴结转移和预后相关，可能成为胃癌预防和治疗的新靶点。ObjectiveTo explore the expressions and clinical values of progastrinreleasing peptide （ProGRP） and carbohydrate antigen 724（CA724） in patients with gastric cancer. MethodsNinety patients with gastric cancer and fifty healthy subjects were selected from January 2014 to December 2016 in our hospital. Serum levels of ProGRP and CA724 were detected by electrochemiluminescence. The relationships between ProGRP and clinicopathological characteristics, postoperative recurrence and CA724 were analyzed. The diagnostic values of ProGRP and CA724 in gastric cancer were analyzed by receiver operating characteristic （ROC） curve. ResultsThe expressions of ProGRP and CA724 in patients with gastric cancer were （249.3±28.9）pg/ml and （148.8±33.5）U/ml respectively, which were significantly higher than those of healthy subjects [（14.4±7.6）pg/ml and （3.8±1.4）U/ml], and the differences were statistically sigificant （t=56.320, P〈0.001; t=30.504, P〈0.001）. The expression of ProGRP in TNM stage ⅢⅣ [（269.1±30.9）pg/ml] was obviously higher than that in stage ⅠⅡ [（198.5±23.9）pg/ml], with a significant difference （t=11.200, P〈0.001）. The expression of ProGRP in patients with lymph node metastasis [（259.9±31.4）pg/ml] was significantly higher than that in patients without lymph node metastasis [（190.3±26.8）pg/ml], with a significant difference （t=9.500, P〈0.001）. The expression of ProGRP in patients with postoperative recurrence after one year [（181.3±21.7）pg/ml] was higer than that in patients without postoperative recurrence [（26.1±12.8）pg/ml], with a significant difference （t=31.830, P〈0.001）. There was a positive correlation between serum ProGRP and CA724 （r=0.792, P=0.012）. According to the ROC curve, the cutoff point of ProGRP was 23.6 pg/ml, and the diagnostic sensitivity was 80.0%, the specificity was 70.0%. The cutoff point of CA724 was 11.2 U/ml, and the diagnostic sensitivity was 60.0%,

关 键 词：胃肿瘤 胃泌素释放肽前体 糖类抗原72-4 

分 类 号：R735.2[医药卫生—肿瘤]